关于首次公开发行部分限售股上市流通的公告 本公司董事会及除董事长范志和先生外的全体董事保证本公告内容不存在 任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整 性依法承担法律责任。 重要内容提示： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 1 月 25 日出具的《关于同意上海赛 伦生物技术股份有限公司首次公开发行股票注册的批复》（证监许可【2022】204 号），同意公司首次公开发行股票的注册申请。公司首次向社会公众公开发行人 民币普通股（A 股）股票 27,060,000 股，并于 2022 年 3 月 11 日在上海证券交易 所科创板上市，发行完成后股本总数为 108,220,000 股，其中有限售条件流通股 83,456,396 股，占公司股本总数的 77.12%，无限售条件流通股 24,763,604 股，占 公司股本总数的 22.88%。 本次上市流通的限售股为公司首次公开发行部分限售股，原始限售期为自公 司首次公开发行股票上市之日起 12 个月。因触发延长锁定期相关承诺，公司股 东何毅明、成琼、张浩、张志平持有的公司股份在原锁定期的基础上自动延长 ...

方正证券承销保荐有限责任公司 关于上海赛伦生物技术股份有限公司 首次公开发行部分限售股上市流通的核查意见 方正证券承销保荐有限责任公司（以下简称"保荐机构"）作为上海赛伦生 物技术股份有限公司（以下简称"公司"或"赛伦生物"）首次公开发行股票并 在科创板上市及持续督导的保荐机构，根据《上海证券交易所科创板股票上市规 则（2020 年 12 月修订）》《上海证券交易所科创板上市公司自律监管指引第 1 号 —规范运作》以及《科创板上市公司持续监管办法（试行）》等相关规定，对赛 伦生物首次公开发行部分限售股上市流通事项进行了核查，情况如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 1 月 25 日出具的《关于同意上海赛 伦生物技术股份有限公司首次公开发行股票注册的批复》（证监许可[2022]204 号），同意公司首次公开发行股票的注册申请。公司首次向社会公众公开发行人 民币普通股（A 股）股票 27,060,000 股，并于 2022 年 3 月 11 日在上海证券交易 所科创板上市，发行完成后股本总数为 108,220,000 股，其中有限售条件流通股 83,456,396 股， ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2023, representing a 20% increase compared to the same period last year[14]. - The company's operating revenue for the first half of 2023 was ¥93,759,588.31, an increase of 19.88% compared to ¥78,210,546.60 in the same period last year[20]. - The net profit attributable to shareholders decreased by 11.67% to ¥26,909,324.11 from ¥30,463,090.64 year-on-year[22]. - The net cash flow from operating activities dropped significantly by 188.62%, resulting in a negative cash flow of ¥18,887,952.07[22]. - The company's total assets decreased by 4.87% to ¥1,106,471,391.92 from ¥1,163,066,774.97 at the end of the previous year[20]. - The basic earnings per share fell by 21.88% to ¥0.25 from ¥0.32 in the same period last year[21]. - The company's net assets attributable to shareholders decreased by 4.81% to ¥1,067,375,597.95 from ¥1,121,290,451.58 at the end of the previous year[20]. - The company reported a decrease in gross profit margin due to rising product sales costs and increased selling and R&D expenses[22]. - The company achieved a net profit attributable to shareholders of 26.91 million yuan in the first half of 2023, a decrease of 11.67% compared to the same period last year, primarily due to a decline in sales of tetanus immunoglobulin and increased production costs[64]. Research and Development - Research and development expenses accounted for 9.60% of operating revenue, an increase of 2.20 percentage points compared to 7.40% in the previous year[21]. - The company has achieved a 55.46% increase in research and development (R&D) expenses, totaling ¥9,002,649.30 compared to ¥5,791,126.70 in the same period last year[50]. - R&D expenses for the period amounted to CNY 9.00 million, representing a year-on-year increase of 55.46% due to increased investment in new projects[63]. - The company is developing a rapid diagnostic reagent for snake venom with a total investment of CNY 13.50 million, currently in the preclinical research stage[53]. - The company has ongoing R&D projects with a total investment of CNY 230.85 million, of which CNY 8.86 million was invested in the current period, and cumulative investment reached CNY 78.95 million[53]. - The company has developed various immune adjuvants to enhance the immune response, crucial for producing high-efficacy antiserum[43]. - The company has focused on toxin proteomics research to analyze pathogenic mechanisms and develop effective antitoxin drugs[41]. - The company has developed antigen purification technology that maintains high antigenicity while ensuring the inactivation of toxins[42]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[14]. - The company continues to expand its market presence, particularly in the sales of antivenom serum and tetanus immunoglobulin products, which saw year-on-year growth[22]. - The company has provided a forward guidance of 10% revenue growth for the second half of 2023, projecting total revenue to reach approximately 550 million CNY[14]. - New product development includes the launch of a novel immunoglobulin product, expected to contribute an additional 50 million CNY in revenue by the end of 2023[14]. - The company is actively pursuing technology upgrades and new product development to strengthen its core competitiveness and expand its market presence[63]. Risks and Challenges - The company has identified potential risks related to regulatory changes, which could impact future product approvals and market access[14]. - The company faces risks related to the concentration of suppliers for horses used in the production of its main products, which could impact production stability if suppliers fail to meet requirements[71]. - The company's main revenue sources are relatively concentrated in anti-snake venom serum and tetanus immunoglobulin, posing risks if sales or market prices decline significantly[72]. - The company’s products are included in the National Essential Medicines List, but future adjustments to this list could adversely affect operations[75]. - The company faces risks related to the uncertainty of drug development success and potential impairment of long-term equity investments[79]. Environmental and Compliance - The company has established pollution control facilities, including ammonium sulfate recovery and activated carbon purification systems, to ensure compliance with environmental regulations[102]. - The company has implemented automatic online monitoring for wastewater discharge to ensure compliance with environmental standards[102]. - The company has a comprehensive emergency response plan for environmental incidents, updated in 2023[103]. - The company has developed a 2023 environmental self-monitoring plan, establishing monitoring standards for air, water, noise, soil, and groundwater[104]. - The company has committed to strict compliance with national environmental monitoring technical standards and quality management regulations[104]. Shareholder and Governance - The company held a shareholders' meeting on May 15, 2023, where all proposals were approved without any rejections[93]. - The company did not propose any profit distribution or capital reserve transfer plans for the first half of the year[96]. - Major shareholders have pledged not to transfer or manage their shares during the lock-up period, with a commitment to maintain the share price above the IPO price for two years post-lock-up[112]. - The company has committed to a share lock-up period of 36 months for major shareholders following the IPO[110]. - The company emphasizes compliance with legal responsibilities regarding share transfers and lock-up commitments[120]. Fundraising and Financial Management - The company reported a total fundraising amount of ¥893,791,800, with a net amount of ¥784,923,575 after deducting issuance costs[173]. - As of the end of the reporting period, the cumulative investment of raised funds reached ¥143,285,582.91, representing an investment progress of 18.25%[173]. - The company approved the use of RMB 115 million of raised funds to permanently supplement working capital, accounting for 29.88% of the total raised funds[177]. - The company has approved the use of up to RMB 700 million of idle raised funds for cash management, with a usage period not exceeding 12 months[176]. - The company will strengthen fundraising management to mitigate risks associated with fund usage and ensure compliance with relevant regulations[133].

方正证券承销保荐有限责任公司 关于上海赛伦生物技术股份有限公司 部分募投项目延期的核查意见 方正证券承销保荐有限责任公司（以下简称"保荐机构"）作为上海赛伦生 物技术股份有限公司（以下简称"公司"或"赛伦生物"）首次公开发行股票并 在科创板上市及持续督导的保荐机构，根据《上海证券交易所科创板股票上市规 则（2020 年 12 月修订）》《上海证券交易所科创板上市公司自律监管指引第 1 号 —规范运作》《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管 要求》以及《科创板上市公司持续监管办法（试行）》等相关规定，对赛伦生物 部分募投项目延期的事项进行了审慎核查，情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]204 号）的批准，公司获准向社会 公开发行人民币普通股 2,706 万股，每股面值为 1.00 元，每股发行价格为 33.03 元，公司收到募集资金总额为 89,379.18 万元，扣除发行费用 10,886.82 万元，募 集资金净额为 78,492.36 万元。上述募集资金已于 2022 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2023-021 上海赛伦生物技术股份有限公司 关于部分募投项目延期的公告 本公司董事会及除董事长范志和先生外的全体董事保证本公告内容不存在 任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整 性依法承担法律责任。 上海赛伦生物技术股份有限公司（以下简称"公司"）于 2023 年 8 月 28 日 分别召开第三届董事会第十五次会议、第三届监事会第十一次会议，审议通过了 《关于部分募投项目延期的议案》，同意公司对募投项目"上海赛伦生物技术股 份有限公司厂房扩建项目"达到预定可使用状态的时间进行延期。独立董事对本 事项发表了明确同意的独立意见，保荐机构方正证券承销保荐有限责任公司（以 下简称"方正证券"或"保荐机构"）对本事项出具了明确的核查意见。上述议 案无需提交公司股东大会审议。现将相关情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可【2022】204 号）的批准，公司获准向社 会公开发行人民币普通股 2,706 万股，每股面值为 1.00 元 ...

上海赛伦生物技术股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及除董事长范志和先生外的全体董事保证本公告内容不存在 任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求》、《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等有关规定，现将上海赛伦生物技术股份有限公司（以下简称"公司"）2023年 半年度募集资金存放与实际使用情况专项报告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司 首次公开发行股票注册的批复》（证监许可【2022】204 号）的批准，公司获准 向社会公开发行人民币普通股 2,706 万股，每股面值为 1.00 元，每股发行价格 为 33.03 元，公司收到募集资金总额为 89,379.18 万元，扣除发行费用 10,886.82 万元，募集资金净额为 78,492.36 万元。上述募集资金已于 2022 年 3 月 4 日全部 到位，并存放于募集资金专项账户内。天职国际会计师事 ...

上海赛伦生物技术股份有限公司 独立董事关于第三届董事会第十五次会议 相关事项的独立意见 会对公司的正常经营产生重大不利影响。决策和审议程序符合《上市公司监管指 引第 2 号—上市公司募集资金管理和使用的监管要求》《上海证券交易所科创板 上市公司自律监管指引第 1 号—规范运作》等相关法律法规及公司《募集资金管 理制度》的规定，不存在变相改变募集资金投向和损害股东特别是中小股东利益 的情形。 综上，我们一致同意《关于部分募投项目延期的议案》。 第三届董事会第十五次会议决议通过《关于公司 2023 年半年度募集资金存 放与实际使用情况的专项报告的议案》的程序规范，符合《公司法》《证券法》 《上市规则》《公司章程》等有关规定。 综上，我们一致同意《关于公司 2023 年半年度募集资金存放与实际使用情 况的专项报告的议案》。 二、对《关于部分募投项目延期的议案》发表独立意见 本次部分募投项目延期是公司根据项目实施的实际情况做出的审慎决定，不 1 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、《上海证券交易所科创板股票上市规则》（以 下简称"《上市规则》" ...

第三届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会的召开情况 证券代码：688163 证券简称：赛伦生物 公告编号：2023-022 上海赛伦生物技术股份有限公司 上海赛伦生物技术股份有限公司（以下简称"公司"）第三届监事会第十一 次会议（以下简称"本次会议"）于 2023 年 8 月 28 日以现场结合通讯方式召开， 本次会议通知及相关材料已于 2023 年 8 月 17 日以书面方式送达公司全体监事。 公司监事 3 人，实际出席监事 3 人。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律法 规、规范性文件和《上海赛伦生物技术股份有限公司章程》《上海赛伦生物技术 股份有限公司监事会议事规则》的有关规定，会议形成的决议合法、有效。 二、 监事会会议审议情况 经与会监事投票表决，审议通过了如下议案： 1、审议通过《关于公司 2023 年半年度报告及摘要的议案》 根据《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运 ...

重要内容提示： 会议召开时间：2023 年 5 月 29 日（星期一）下午 13:00-14:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 证券代码：688163 证券简称：赛伦生物 公告编号：2023-016 上海赛伦生物技术股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩暨现金分红 说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 投资者可于 2023 年 5 月 22 日（星期一）至 5 月 26 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 dmb@serum-china.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海赛伦生物技术股份有限公司（以下简称"公司"）已于 2023 年 4 月 21 日发布公司 2022 年年度报告、2022 年度利润分配方案及 2023 ...

Financial Performance - The company's operating revenue for 2022 was CNY 174,221,005.91, a decrease of 16.52% compared to CNY 208,693,627.46 in 2021[20]. - The net profit attributable to shareholders for 2022 was CNY 64,135,803.84, down 16.14% from CNY 76,482,795.73 in the previous year[20]. - The net profit after deducting non-recurring gains and losses decreased by 35.71% to CNY 44,693,930.62 from CNY 69,513,945.85 in 2021[21]. - The net cash flow from operating activities fell by 26.41% to CNY 67,913,773.25 compared to CNY 92,288,488.20 in 2021[21]. - The company's total assets increased by 188.68% to CNY 1,163,066,774.97 at the end of 2022, up from CNY 402,891,055.95 at the end of 2021[21]. - The net assets attributable to shareholders grew by 203.36% to CNY 1,121,290,451.58 at the end of 2022, compared to CNY 369,629,071.96 at the end of 2021[21]. - Basic earnings per share decreased by 32.98% to CNY 0.63 in 2022 from CNY 0.94 in 2021[22]. - The company's revenue from the biopharmaceutical sector was approximately 174.22 million, with a gross margin of 83.77%, reflecting a slight increase of 0.18 percentage points compared to the previous year[112]. Dividend Distribution - The proposed profit distribution plan for 2022 is to distribute a cash dividend of RMB 7.50 per 10 shares (including tax), totaling RMB 81,165,000, which accounts for 126.55% of the net profit attributable to shareholders in 2022[5]. - In 2021, the company distributed cash dividends of RMB 97,398,000, which accounted for 127.35% of the net profit attributable to shareholders[190]. - The company has a well-defined decision-making process for dividend distribution, ensuring transparency and protection of minority shareholders' rights[191]. Research and Development - The R&D expenditure as a percentage of operating revenue was 8.87%, down 3.47 percentage points from 12.34% in 2021[22]. - The company has invested a total of ¥15,457,131.29 in R&D for the year, a decrease of 40% compared to ¥25,763,088.98 in the previous year[75]. - The company has applied for 6 new invention patents during the reporting period[33]. - The company is currently conducting clinical trials for the anti-viper venom serum, with a total investment of ¥1,600,000 and ¥1,065,400 invested to date[77]. - The company has developed proprietary technologies for toxin protein research, enabling effective analysis and purification of toxic components for the development of antitoxin drugs[65]. - The company is engaged in ongoing research and development of new technologies to enhance the quality of antivenoms and antitoxins, ensuring affordability and high production capacity[63]. Market Position and Strategy - The company is the only domestic producer and seller of snake antivenom, fulfilling emergency clinical needs in the public health sector[37]. - The company has a comprehensive competitive advantage in the field of antivenom and antitoxin drugs, supported by a rich R&D and technical team, GMP-certified production facilities, and a nationwide medical promotion team[36]. - The biopharmaceutical market in China is projected to reach RMB 1,319.8 billion by 2030, with a compound annual growth rate (CAGR) of 10.9% from 2023 to 2030[48]. - The company aims to enhance product promotion and coverage to reduce fatalities and disabilities caused by snakebites in China[53]. - The company is positioned to leverage its unique market position and advanced technology to expand its product offerings and market share[52]. Risk Management - The company has detailed various risks faced during operations in the report, emphasizing the importance of risk management[4]. - The report includes a forward-looking statement risk disclaimer, cautioning investors about potential uncertainties in future plans[6]. - The company faces risks related to price control or competition that could lead to a decrease in product prices and impact revenue growth[91]. - The company has a risk of product safety due to potential pathogens remaining in the plasma used for production, despite implementing screening and virus inactivation measures[90]. Corporate Governance - The company has established a standardized corporate governance structure in compliance with relevant laws and regulations, holding one shareholders' meeting and six board meetings during the reporting period[157]. - The company has implemented strict information disclosure practices, ensuring timely and accurate communication with investors and stakeholders[158]. - The company maintains independence from its controlling shareholder, ensuring no non-operational use of company funds[157]. - The company has established a comprehensive internal control system to ensure effective governance and risk management, covering various aspects including financial management and major investments[197]. Employee Management - The company emphasizes employee training, implementing various training programs to enhance skills and professional knowledge[187]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 5.6352 million RMB[174]. - The company has a competitive and equitable salary policy, aiming to motivate employees and enhance their performance[186]. - The number of R&D personnel has increased to 41, accounting for 13.31% of the total workforce, compared to 40 personnel and 13.56% in the previous year[80].